In this free webinar, oncology experts will discuss what ASCO 2026 data could mean for cancer clinical trials and patient ...

Earlier this year, Daiichi Sankyo Global Head of Oncology Ken Keller told pharmaphorum about the company’s big year, with ...

Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01.

ImmunityBio (NasdaqGS:IBRX) presented new clinical data on ANKTIVA in advanced non small cell lung cancer and BCG unresponsive non muscle invasive bladder cancer at the 2026 ASCO Annual Meeting. The ...

For GSK, ASCO 2026 was about long-term follow-up data, with new data from ongoing trials of Jemperli and Blenrep. Eric ...

Tempus AI (NasdaqGS:TEM) has launched the ArteraAI Prostate Test, its first externally developed AI-powered digital pathology test for metastatic hormone-sensitive prostate cancer. The test is ...

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for the last day here. ASCO is more than half done. There is ...

As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial edge.

Thousands of cancer researchers and clinicians are flocking to Chicago for the American Society of Clinical Oncology annual meeting that starts Friday. The ASCO meeting is where clinicians expect to ...

Global Initiatives to Enhance Cancer Care in Areas of Limited Resources: What ASCO Members Are Doing and How You Can Become Involved ASCO is an international oncology society dedicated to serving its ...